Dr. Richard J. Ablin first discovered PSA in 1970 and for the last two decades since the FDA approved its use, PSA remains the standard biomarker for diagnosis, screening and monitoring of prostate cancer despite having many flaws. This evidence concerns the gene KLK3 and prostate carcinoma.